Impact of U.S. Most-Favored-Nation Pricing Model on Global Product Launches & Pricing

In May 2025, President Donald Trump signed the executive order introducing a ‘Most-Favored-Nation’ pricing model, aimed at equalizing U.S. drug prices with similar prices in “comparably developed nations”. Driving U.S. pricing toward international benchmarks is forcing manufacturers to recalibrate global ex-U.S. launch and pricing strategies. In this resource, we explore the challenges and opportunities this presents for our clients. Please complete the form to the right to download.